$TMDX
TransMedics Group, Inc.

2020 Q4 Form 10-K Financial Statement

#000156459021012527 Filed on March 11, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2020 Q2
Revenue $7.627M $7.091M $3.391M
YoY Change 25.92% -1.58% -40.15%
Cost Of Revenue $2.800M $2.050M $1.480M
YoY Change 20.69% -31.42% -36.48%
Gross Profit $4.828M $5.038M $1.909M
YoY Change 29.06% 19.5% -42.72%
Gross Profit Margin 63.3% 71.05% 56.3%
Selling, General & Admin $6.180M $5.490M $5.870M
YoY Change 0.16% -15.78% -6.08%
% of Gross Profit 128.0% 108.97% 307.49%
Research & Development $4.550M $4.160M $3.900M
YoY Change -27.32% -15.77% -18.58%
% of Gross Profit 94.24% 82.57% 204.3%
Depreciation & Amortization $430.0K $400.0K $380.0K
YoY Change 22.86% 17.65% 35.71%
% of Gross Profit 8.91% 7.94% 19.91%
Operating Expenses $10.72M $9.650M $9.770M
YoY Change -13.76% -15.78% -11.5%
Operating Profit -$5.896M -$4.610M -$7.861M
YoY Change -32.18% -36.34% 2.02%
Interest Expense -$410.0K -$470.0K -$630.0K
YoY Change -12.77% -143.36% -27.59%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$6.300M -$5.080M -$8.491M
YoY Change -31.3% -38.57% -7.56%
Income Tax $10.00K $10.00K $10.00K
% Of Pretax Income
Net Earnings -$6.311M -$5.088M -$8.497M
YoY Change -31.23% -38.55% -7.59%
Net Earnings / Revenue -82.75% -71.75% -250.58%
Basic Earnings Per Share
Diluted Earnings Per Share -$232.4K -$187.4K -$0.36
COMMON SHARES
Basic Shares Outstanding 23.33M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $125.6M $132.7M $139.4M
YoY Change 525.12% 50.28% 44.91%
Cash & Equivalents $24.58M $21.40M $51.15M
Short-Term Investments $101.1M $111.3M $88.20M
Other Short-Term Assets $2.300M $2.300M $1.900M
YoY Change 53.33% 9.52% 18.75%
Inventory $11.93M $13.00M $12.60M
Prepaid Expenses
Receivables $6.864M $6.100M $4.400M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $146.8M $154.1M $158.2M
YoY Change 46.76% 43.48% 36.22%
LONG-TERM ASSETS
Property, Plant & Equipment $4.754M $4.700M $4.400M
YoY Change -0.79% 0.0% 0.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.000K $500.0K $500.0K
YoY Change 0.0% 8233.33% 8233.33%
Total Long-Term Assets $5.260M $5.200M $4.900M
YoY Change -0.72% 0.0% 0.39%
TOTAL ASSETS
Total Short-Term Assets $146.8M $154.1M $158.2M
Total Long-Term Assets $5.260M $5.200M $4.900M
Total Assets $152.0M $159.3M $163.1M
YoY Change 44.38% 41.47% 34.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.206M $800.0K $3.700M
YoY Change -83.36% -83.33% -44.46%
Accrued Expenses $10.30M $11.50M $8.900M
YoY Change 24.1% 23.66% 8.54%
Deferred Revenue $263.0K
YoY Change 58.43%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $11.88M $13.60M $13.80M
YoY Change -26.29% -7.11% -10.26%
LONG-TERM LIABILITIES
Long-Term Debt $34.66M $34.53M $34.40M
YoY Change 1.5% 1.48% 1.47%
Other Long-Term Liabilities $1.600M $1.600M $1.200M
YoY Change 300.0% 220.0% 100.0%
Total Long-Term Liabilities $34.66M $34.53M $35.60M
YoY Change 1.5% 1.48% 5.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.88M $13.60M $13.80M
Total Long-Term Liabilities $34.66M $34.53M $35.60M
Total Liabilities $48.14M $49.77M $49.40M
YoY Change -4.97% 1.27% -0.91%
SHAREHOLDERS EQUITY
Retained Earnings -$391.9M
YoY Change 8.77%
Common Stock $502.2M $501.5M
YoY Change 18.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $103.9M $109.6M $113.8M
YoY Change
Total Liabilities & Shareholders Equity $152.0M $159.3M $163.1M
YoY Change 44.35% 41.47% 34.79%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$6.311M -$5.088M -$8.497M
YoY Change -31.23% -38.55% -7.59%
Depreciation, Depletion And Amortization $430.0K $400.0K $380.0K
YoY Change 22.86% 17.65% 35.71%
Cash From Operating Activities -$7.140M -$6.410M -$8.540M
YoY Change -1.79% 14.67% -29.77%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$50.00K -$120.0K
YoY Change -200.0% 66.67% -20.0%
Acquisitions
YoY Change
Other Investing Activities $9.890M -$23.42M -$40.60M
YoY Change 34.74% 25.04% -17.06%
Cash From Investing Activities $9.880M -$23.47M -$40.73M
YoY Change 34.24% 25.11% -17.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.00K -180.0K 75.55M
YoY Change -112.0% -92.59% -21.38%
NET CHANGE
Cash From Operating Activities -7.140M -6.410M -8.540M
Cash From Investing Activities 9.880M -23.47M -40.73M
Cash From Financing Activities 30.00K -180.0K 75.55M
Net Change In Cash 2.770M -30.06M 26.28M
YoY Change -1831.25% 12.25% -24.57%
FREE CASH FLOW
Cash From Operating Activities -$7.140M -$6.410M -$8.540M
Capital Expenditures -$10.00K -$50.00K -$120.0K
Free Cash Flow -$7.130M -$6.360M -$8.420M
YoY Change -2.06% 14.39% -29.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27370038
CY2020 dei Entity File Number
EntityFileNumber
001-38891
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2181531
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Minuteman Road
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Andover
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01810
CY2020 dei City Area Code
CityAreaCode
(978)
CY2020 dei Local Phone Number
LocalPhoneNumber
552-0900
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
790000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3904000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2326000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1538000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
146766000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
100001000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4754000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4792000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6000
CY2019Q4 us-gaap Assets
Assets
105299000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7247000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8332000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
166000
CY2020Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
93000
CY2019Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
370000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
341000
CY2020Q2 dei Entity Public Float
EntityPublicFloat
454400000
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Security12b Title
Security12bTitle
Common Stock, No Par Value
CY2020 dei Trading Symbol
TradingSymbol
TMDX
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24581000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20092000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
101061000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
60596000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6864000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6559000
CY2020Q4 us-gaap Inventory Net
InventoryNet
11934000
CY2019Q4 us-gaap Inventory Net
InventoryNet
11216000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-28716000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-33507000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
40000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-33547000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.36
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24702764
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
9004000
CY2019 us-gaap Gross Profit
GrossProfit
13863000
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16115000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34146000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
389000
CY2020Q4 us-gaap Liabilities
Liabilities
48135000
CY2019Q4 us-gaap Liabilities
Liabilities
50650000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
502217000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11879000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34657000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
424134000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-369483000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
54649000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105299000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020 us-gaap Operating Expenses
OperatingExpenses
43019000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020 us-gaap Revenues
Revenues
25639000
CY2019 us-gaap Revenues
Revenues
23604000
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
9741000
CY2019 us-gaap Operating Expenses
OperatingExpenses
43466000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-26384000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-29603000
CY2020 us-gaap Interest Expense
InterestExpense
3985000
CY2019 us-gaap Interest Expense
InterestExpense
4353000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1653000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2332000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
32000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28748000
CY2020Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
800000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28841000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6000
CY2020Q4 us-gaap Assets
Assets
152026000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1206000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10317000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
263000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1599000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
60542000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
56000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
60596000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14204787
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-49000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
45000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
54000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
99000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33448000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32286000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
455000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
165000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
121793000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
82371000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
80650000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
854000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-192242000
CY2019 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
186519000
CY2019 tmdx Conversion Of Preferred Stock Warrants Into Common Stock Warrants Upon Initial Public Offering
ConversionOfPreferredStockWarrantsIntoCommonStockWarrantsUponInitialPublicOffering
1239000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
91401000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
202000
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
854000
CY2019 tmdx Stock Issued During Period Value Settlement Of Accrued Financing Fee
StockIssuedDuringPeriodValueSettlementOfAccruedFinancingFee
124000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
227000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
357000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75085000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2414000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-49000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28748000
CY2020 tmdx Discounts And Stock Issuance Costs
DiscountsAndStockIssuanceCosts
585000
CY2019 tmdx Discounts And Stock Issuance Costs
DiscountsAndStockIssuanceCosts
5966000
CY2020 us-gaap Profit Loss
ProfitLoss
-28748000
CY2019 us-gaap Profit Loss
ProfitLoss
-33547000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1577000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1222000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2414000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
854000
CY2020 tmdx Non Cash Interest And End Of Term Accretion Expense
NonCashInterestAndEndOfTermAccretionExpense
511000
CY2019 tmdx Non Cash Interest And End Of Term Accretion Expense
NonCashInterestAndEndOfTermAccretionExpense
475000
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
634000
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-205000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1065000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-200000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
218000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3166000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1740000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4121000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
769000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-250000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5802000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3443000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1948000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2453000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
60000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-136000
CY2020 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-933000
CY2019 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
349000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30265000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
22035000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41598000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60501000
CY2020 tmdx Proceeds From Issuance Of Common Stock In Initial Public Offering Net Of Underwriting Discounts And Commissions
ProceedsFromIssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndCommissions
75670000
CY2019 tmdx Proceeds From Issuance Of Common Stock In Initial Public Offering Net Of Underwriting Discounts And Commissions
ProceedsFromIssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndCommissions
97367000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
705000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4846000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
227000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
202000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
357000
CY2020 tmdx Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
2249000
CY2020 tmdx Repayment Of Paycheck Protection Program Loan
RepaymentOfPaycheckProtectionProgramLoan
2249000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75549000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
92723000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
803000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-85000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4489000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-149000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20592000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20741000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25081000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
3475000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
3877000
CY2019 tmdx Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering
ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering
186519000
CY2020 tmdx Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
1191000
CY2019 tmdx Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
2146000
CY2019 tmdx Reclassification Of Warrant Liability To Equity Upon Initial Public Offering
ReclassificationOfWarrantLiabilityToEquityUponInitialPublicOffering
1239000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
169000
CY2019 tmdx Offering Costs Included In Accounts Payable And Accrued Expenses
OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
120000
CY2019 tmdx Settlement Of Accrued Financing Fee
SettlementOfAccruedFinancingFee
124000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
500000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
500000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the valuation of inventory and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. <font style="Background-color:#FFFFFF;color:#212529;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. </font><font style="color:#000000;">As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. </font>Actual results may differ from those estimates or assumptions. </p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risk of Concentrations of Credit, Significant Customers and Significant Suppliers </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company has not experienced any other-than-temporary losses with respect to its cash, cash equivalents and marketable securities and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers are those that accounted for 10% or more of the Company&#8217;s total revenue or accounts receivable. For the fiscal year ended December 31, 2020, two customers represented 14% and 10% of net revenue, respectively. For the fiscal year ended December 28, 2019, no customer accounted for 10% or more of net revenue. As of December 31, 2020, one customer accounted for 30% of accounts receivable. As of December 28, 2019, no customer accounted for 10% or more of accounts receivable.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the components and subassemblies included in the Company&#8217;s products are obtained from a sole source, a single source or a limited group of suppliers. Although the Company seeks to reduce dependence on those limited sources of suppliers and manufacturers, the partial or complete loss of certain of these sources could have a material adverse effect on the Company&#8217;s operating results, financial condition and cash flows and damage its customer relationships. </p>
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
125600000
CY2020Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
500000
CY2019Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
500000
CY2020 tmdx Number Of Letters Of Credit Maintained
NumberOfLettersOfCreditMaintained
2
CY2019 tmdx Number Of Letters Of Credit Maintained
NumberOfLettersOfCreditMaintained
2
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q4 us-gaap Capitalized Software Development Costs For Software Sold To Customers
CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers
0
CY2019Q4 us-gaap Capitalized Software Development Costs For Software Sold To Customers
CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers
0
CY2020Q4 us-gaap Provision For Loss On Contracts
ProvisionForLossOnContracts
0
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 tmdx Term Of Product Warranties
TermOfProductWarranties
P1Y
CY2020 us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
The Company provides a one-year warranty on its OCS Consoles and disposable sets and replaces or repairs any OCS Console or disposable set that does not function in accordance with the product specifications
CY2020 tmdx Clinical Trial Expense
ClinicalTrialExpense
2717000
CY2019 tmdx Clinical Trial Expense
ClinicalTrialExpense
2240000
CY2020 tmdx Research Development And Clinical Trials Expenses
ResearchDevelopmentAndClinicalTrialsExpenses
1600000
CY2019 tmdx Research Development And Clinical Trials Expenses
ResearchDevelopmentAndClinicalTrialsExpenses
1200000
CY2020 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
Payment terms for customer orders, including for each of the Company’s primary performance obligations, are typically 30 days for customers in the United States and 30 to 90 days for customers in non-U.S. markets, and such payments do not include payments that are variable, dependent on specified factors or events.
CY2020Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2019Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28356000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25844000
CY2020 us-gaap Revenues
Revenues
25639000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2340625
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2016740
CY2020 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
greater than 50%
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
101050000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
101061000
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
13829000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
114890000
CY2019Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
11760000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
72356000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6770000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4881000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1102000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
903000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4062000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5432000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12781000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11139000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8027000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6347000
CY2019Q4 tmdx Accrued Research Development And Clinical Trials Expenses Current
AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent
3144000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3604000
CY2019Q4 tmdx Accrued Financing Fees Current
AccruedFinancingFeesCurrent
120000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
344000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
537000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1517000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
927000
CY2019Q4 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
285000
CY2019Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
13119424
CY2019Q2 tmdx Preferred Stock Warrants Shares Issued Upon Conversion
PreferredStockWarrantsSharesIssuedUponConversion
64440
CY2019Q2 tmdx Shares Authorized
SharesAuthorized
175000000
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2019Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote on all matters submitted to a vote of the Company’s stockholders. The holders of common stock, voting exclusively and as a separate class, are entitled to elect two directors of the Company
CY2020 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
26671000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
22363000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2900000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2300000
CY2020 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2019Q2 tmdx Number Of Vote Entitled For Each Share Of Common Stock
NumberOfVoteEntitledForEachShareOfCommonStock
1
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0091
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0229
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y0M7D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.54
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.52
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.91
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.55
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2414000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5900000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1952300
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
603336
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
217965
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
65566
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
10871
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2261234
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2261234
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1425910
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.31
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.69
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.04
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.01
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
43.96
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.17
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.17
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.26
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M14D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M19D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y2M19D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y8M23D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
26415000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
26671000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-28803000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-33668000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
87000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
161000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-28716000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.057
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.036
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.028
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.002
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.002
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
6136000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.078
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2020 tmdx Effective Income Tax Rate Reconciliation Return To Provision
EffectiveIncomeTaxRateReconciliationReturnToProvision
-0.017
CY2019 tmdx Effective Income Tax Rate Reconciliation Return To Provision
EffectiveIncomeTaxRateReconciliationReturnToProvision
0.000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.009
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.209
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.290
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
81390000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
74206000
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
8505000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11541000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
10745000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1390000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1309000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
791000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
243000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
79000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
157000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
132000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
101459000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
95165000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
218000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
141000
CY2020Q4 tmdx Deferred Tax Liabilities Unrealized Gain Loss
DeferredTaxLiabilitiesUnrealizedGainLoss
212000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
430000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
141000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
101029000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
95024000
CY2020 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period.
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6000000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
85316000
CY2020 tmdx Deferred Tax Assets Valuation Allowance Increases Recorded To Income Tax Provision
DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision
6005000
CY2019 tmdx Deferred Tax Assets Valuation Allowance Increases Recorded To Income Tax Provision
DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision
9708000
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1800000
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1200000
CY2020Q4 tmdx Tenant Improvements Allowance Receivable
TenantImprovementsAllowanceReceivable
0
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1900000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1948000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1997000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2047000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2098000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
4354000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
14344000
CY2020 us-gaap Payments For Royalties
PaymentsForRoyalties
300000
CY2019 us-gaap Payments For Royalties
PaymentsForRoyalties
300000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
100000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020Q4 us-gaap Noncurrent Assets
NoncurrentAssets
4754000
CY2019Q4 us-gaap Noncurrent Assets
NoncurrentAssets
4792000
CY2020Q4 us-gaap Revenues
Revenues
7627000
CY2020Q3 us-gaap Revenues
Revenues
7091000
CY2020Q2 us-gaap Revenues
Revenues
3391000
CY2020Q1 us-gaap Revenues
Revenues
7530000
CY2019Q4 us-gaap Revenues
Revenues
6057000
CY2019Q3 us-gaap Revenues
Revenues
7205000
CY2019Q2 us-gaap Revenues
Revenues
5666000
CY2019Q1 us-gaap Revenues
Revenues
4676000
CY2020Q4 us-gaap Gross Profit
GrossProfit
4828000
CY2020Q3 us-gaap Gross Profit
GrossProfit
5038000
CY2020Q2 us-gaap Gross Profit
GrossProfit
1909000
CY2020Q1 us-gaap Gross Profit
GrossProfit
4860000
CY2019Q4 us-gaap Gross Profit
GrossProfit
3741000
CY2019Q3 us-gaap Gross Profit
GrossProfit
4216000
CY2019Q2 us-gaap Gross Profit
GrossProfit
3333000
CY2019Q1 us-gaap Gross Profit
GrossProfit
2573000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5896000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4610000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7861000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8017000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-8694000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7242000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7705000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5962000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-6311000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5088000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8497000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8852000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-9177000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-8280000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-9195000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-6895000
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.86

Files In Submission

Name View Source Status
0001564590-21-012527-index-headers.html Edgar Link pending
0001564590-21-012527-index.html Edgar Link pending
0001564590-21-012527.txt Edgar Link pending
0001564590-21-012527-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gupe1zua53yx000001.jpg Edgar Link pending
gupe1zua53yx000002.jpg Edgar Link pending
gupe1zua53yx000003.jpg Edgar Link pending
gupe1zua53yx000004.jpg Edgar Link pending
gupe1zua53yx000005.jpg Edgar Link pending
gupe1zua53yx000006.jpg Edgar Link pending
gupe1zua53yx000007.jpg Edgar Link pending
gupe1zua53yx000008.jpg Edgar Link pending
gupe1zua53yx000009.jpg Edgar Link pending
gupe1zua53yx000010.jpg Edgar Link pending
gupe1zua53yx000011.jpg Edgar Link pending
gupe1zua53yx000012.jpg Edgar Link pending
gupe1zua53yx000013.jpg Edgar Link pending
gupe1zua53yx000014.jpg Edgar Link pending
gupe1zua53yx000015.jpg Edgar Link pending
gupe1zua53yx000016.jpg Edgar Link pending
gupe1zua53yx000017.jpg Edgar Link pending
gupe1zua53yx000018.jpg Edgar Link pending
gupe1zua53yx000019.jpg Edgar Link pending
gupe1zua53yx000020.jpg Edgar Link pending
gupe1zua53yx000021.jpg Edgar Link pending
gupe1zua53yx000022.jpg Edgar Link pending
gupe1zua53yx000023.jpg Edgar Link pending
gupe1zua53yx000024.jpg Edgar Link pending
gupe1zua53yx000025.jpg Edgar Link pending
gupe1zua53yx000026.jpg Edgar Link pending
gupe1zua53yx000027.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmdx-10k_20201231.htm Edgar Link pending
tmdx-20201231.xml Edgar Link completed
tmdx-20201231.xsd Edgar Link pending
tmdx-20201231_cal.xml Edgar Link unprocessable
tmdx-20201231_def.xml Edgar Link unprocessable
tmdx-20201231_lab.xml Edgar Link unprocessable
tmdx-20201231_pre.xml Edgar Link unprocessable
tmdx-ex231_18.htm Edgar Link pending
tmdx-ex311_8.htm Edgar Link pending
tmdx-ex312_10.htm Edgar Link pending
tmdx-ex321_17.htm Edgar Link pending
tmdx-ex322_12.htm Edgar Link pending